Interferon-β PEGylation Selectivity via Localized Lysine Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for PEGylation of interferon-β result in significant reduction of biological activity, especially when high molecular weight polyethylene glycol is used, leading to decreased effectiveness and increased side effects due to non-selective binding and heterogeneous mixtures.
Innovation Solution
Specifically binding polyethylene glycol to lysine residues at the 19th or 134th position in the interferon-β amino acid sequence, using additives like oligosaccharides and monosaccharides to maintain high interferon-β activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PEG is bound to interferon-β using conventional methods (amino group modification of lysine or N-terminal binding), then PEGylation is achieved, but interferon-β activity decreases to less than 10%
Solution Approach 1:
The patent applies local quality by selectively modifying only specific lysine residues (Lys19, Lys33, Lys108, or Lys134) located in particular regions of the interferon-β molecule, rather than non-selectively modifying all lysine residues. This localized modification approach preserves the biological activity of interferon-β while achieving PEGylation, as demonstrated by maintaining 10% or higher activity even with high molecular weight PEG (20,000-40,000).
Solution Approach 2:
The patent utilizes parameter changes by controlling the pH of the reaction medium to be within a specific range (pH 5.0-8.5) to optimize selective PEG binding to particular lysine residues. This parameter control enables mono-PEGylation at desired positions while preventing non-selective modification, thereby maintaining interferon-β activity.
2Duration of action of moving object
If high molecular weight PEG (20,000-40,000) is used to extend circulatory half-life, then pharmacokinetic properties improve, but interferon-β activity is dramatically decreased or completely lost
Solution Approach 1:
The patent achieves local quality by targeting specific lysine residues (Lys19, Lys33, Lys108, or Lys134) for PEG binding, which allows the use of high molecular weight PEG (20,000-40,000) to extend circulatory half-life while preserving interferon-β activity. The selective modification at these specific positions prevents steric hindrance and maintains biological function, unlike non-selective modification methods.
3Manufacturing precision
If reductive alkylation is used to bind PEG to the amino terminus of interferon, then selective binding is attempted, but non-selective PEGylation occurs at any lysine residue or N terminus, generating heterogeneous mixture
Solution Approach 1:
The patent applies local quality by using pH-controlled conditions (pH 5.0-8.5) to enable selective PEG binding to specific lysine residues (Lys19, Lys33, Lys108, or Lys134) rather than non-selective modification. This localized modification approach produces homogeneous mono-PEGylated interferon-β products with consistent biological activity, avoiding the heterogeneous mixtures generated by reductive alkylation methods.
4Quantity of substance
If non-selective PEGylation is performed to increase PEG binding, then polymer conjugate is formed, but interferon-β activity is reduced and side effects increase
Solution Approach 1:
The patent applies local quality by selectively modifying only specific lysine residues (Lys19, Lys33, Lys108, or Lys134) for PEG binding, which limits the number of PEG molecules bound per interferon-β molecule. This controlled local modification maintains interferon-β activity and reduces side effects compared to non-selective PEGylation that modifies all lysine residues and increases PEG loading.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach maintains 10% or higher interferon-β activity even with high molecular weight PEG, enhancing physical and biological stability, solubility, and circulatory half-life, reducing side effects and improving pharmaceutical efficacy.
Implementation Method 1
polyethylene glycol specifically bound to lysine located at the 19th or 134th position in the amino acid sequence of interferon-β
Data Source
AI summary
The present invention relates to a complex between interferon-β and polyethylene glycol, which has high biological activity, and to a method for producing the complex at high efficiency. Namely, the present invention relates to a method for producing an interferon-β complex comprising binding interferon-β to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, their corresponding sugar alcohols, and C2-6 polyhydric alcohols, and to an interferon-β complex produced by the method, which has polyethylene glycol specifically bound with lysine located at the 19th or 134th position in the amino acid sequence of interferon-β.